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Interaction of the phencyclidine model of schizophrenia and 
nicotine on total and categorized ultrasonic vocalizations in rats
Natashia Swalvea,*, Michele M. Mulhollanda, Tiffany D. Schulza, and Ming Lia
aDepartment of Psychology, University of Nebraska-Lincoln, Lincoln, NE
Abstract
Patients with schizophrenia smoke cigarettes at a higher rate than the general population. We 
hypothesized that a factor in this comorbidity is sensitivity to the reinforcing and reinforcement-
enhancement effects of nicotine.
Phencyclidine (PCP) was used to model behavioral changes resembling negative symptoms of 
schizophrenia in rats. USVs in rats have been used to measure emotional states, with 50 kHz 
USVs indicating positive states and 22 kHz indicating negative. Total and categorized numbers of 
22 and 50 kHz ultrasonic vocalizations (USVs) and USVs during a visual stimulus (e.g. a potential 
measure of reinforcement-enhancement) were examined in rats following .injection ofh PCP (2.0 
mg/kg), and/or nicotine (0.2 or 0.4 mg/kg) daily for 7 days. PCP was then discontinued and all rats 
received nicotine (0.2 mg/kg and 0.4 mg/kg) and PCP (2.0 mg/kg) on 3 challenge days.
PCP acutely decreased 50 kHz vocalizations while repeated nicotine potentiated rates of 
vocalizations, with similar patterns during light presentations. Rats in the PCP and nicotine 
combination groups made more 50 kHz vocalizations compared to control groups on challenge 
days.
We conclude that PCP may produce a reward deficit that is shown by decreased 50 kHz USVs, and 
behaviors post-PCP exposure may best model the comorbidity between schizophrenia and 
nicotine.
Keywords
ultrasonic vocalization; nicotine; phencyclidine; schizophrenia
Introduction
Tobacco use is a serious health problem with approximately 400,000 people dying annually 
in the United States from nicotine-related concerns (Center for Disease Control, 2014). 
Tobacco addiction is an especially severe problem within the population of schizophrenic 
patients; between 50–90% of the schizophrenic population use tobacco in some form, 
compared to 20–35% of the general population of the United States (Kumari & Postma, 
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2005). This increased dependence on tobacco products leads to damaging health problems in 
this subpopulation, shown by increased incidence of cardiovascular and respiratory diseases 
as well as a smoking-related mortality rate that is 2–3 times higher than the general public 
(Buda et al., 1988; Hennekens et al., 2005; Mortensen & Juel, 1990; Saha et al., 2007).
While a number of hypotheses have been proposed as to the factors involved in the 
comorbidity of tobacco use and schizophrenia, there is currently no consensus in the field. A 
number of studies suggest a role of reward in the comorbidity between tobacco use and 
schizophrenia. For example, anhedonia, which is defined as the lack of an ability to gain 
pleasure or reward, is a common symptom seen in many schizophrenics (Gopalaswamy & 
Morgan, 1986). Patients with schizophrenia rank smoking above other natural rewards, more 
so than non-mentally ill subjects (Smith et al., 2002). These findings implicate an alteration 
of reward-related behavior in patients with schizophrenia who smoke, yet there is a patent 
lack of preclinical research on the reward system and reinforcement efficacy in this 
comorbidity.
This study aimed to determine how reward and affective states are affected by nicotine and 
phencyclidine (PCP), which was used to model certain symptoms of schizophrenia in rats. 
Ultrasonic vocalizations have recently come to attention as potential measures of the 
emotional and motivational states of rats, including reward (Panksepp & Burgdorf, 2000; 
Browning et al., 2011; Maier et al., 2012; Mu et al., 2009). Specifically, 50 kHz 
vocalizations are typically emitted in reinforcer-associated contexts (Brunelli et al., 2006; 
Knutson et al., 1998; Panksepp & Burgdorf, 2000; Sales, 1972; Schwarting et al., 2007; 
White et al., 1990) while 22 kHz vocalizations are generally associated with aversive 
situations (Francis, 1977; Jelen et al., 2003; Tonoue et al., 1986; Wohr et al., 2005; Mead et 
al., 2008; Sun et al., 2010). Wright (2010) further categorized vocalizations into 
subcategories that may lead to better classification of emotional and motivational states. To 
date, the few studies examining PCP have shown that PCP decreased tickling-induced 50 
kHz vocalizations and increased 22 kHz vocalizations (Boulay et al., 2013; Tunstall et al., 
2009), behavior suggestive of a more negative affective state after PCP exposure, which may 
be considered a model of anhedonia seen in schizophrenics.
While there have been relatively few studies on the impact of an animal model of 
schizophrenia on USVs, there have been even fewer on nicotine and none on the interaction 
of effects of phencyclidine and nicotine. Data so far suggest that repeated nicotine 
potentiated USVs while acute administration produced no effect (Simola et al., 2012, 2014). 
However, these studies only examined the general reinforcing and potentially aversive 
effects of nicotine. Nicotine has been suggested to have dual reinforcement properties, with 
a relatively weak primary reinforcing effect and a reinforcement-enhancing property, both of 
which contribute to tobacco addiction (Caggiula et al., 2009). The reinforcement-
enhancement effect is typically defined as enhancement by nicotine of the reinforcing effects 
of other non-drug stimuli (Liu et al., 2007) and has been reliably demonstrated in preclinical 
models (Barrett & Odum, 2011; Raiff & Dallery, 2006, 2008, 2009; Thiel et al., 2009). 
While the dual-reinforcement model has been examined in healthy patients, there is no 
research comparing these two properties of nicotine in a preclinical model of schizophrenia 
symptoms and none examining these properties utilizing ultrasonic vocalizations.
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The purpose of this study was threefold. First, PCP produces differential behavioral 
responses after acute and chronic exposure as well as after discontinuation (Jentsch & Roth, 
1999; Mouri et al., 2007; Nabeshima et al., 1983) and these three frequently used treatment 
regimens have not been compared using the ultrasonic vocalization paradigm to evaluate its 
effect on positive and negative affective states. By evaluating the effects of acute and chronic 
treatment in addition to post-cessation of PCP treatment, this study aimed to illuminate 
which treatment regimen may be most sensitive to the effects of nicotine. Second, as 
discussed, this study aimed to show how nicotine interacts with the PCP treatment regimens 
as well as to detail the acute and chronic effects of nicotine in the USV paradigm. Finally, 
this study proposed a putative model of comparing the primary reinforcing and 
reinforcement-enhancement effects of nicotine by examining ultrasonic vocalizations before 
and during a brief visual stimulus. This visual stimulus (VS) is mildly reinforcing to a rat 
(Berlyne & Koenig, 1965; Glow & Russell, 1975) and is frequently used in testing the 
reinforcement-enhancing effect (Barrett & Bevins, 2012; Chaudhri et al., 2007; Donny et al., 
2003; Palmatier et al., 2006). Based on these findings, reinforcement-enhancement was 
hypothesized to be seen as an increase in ultrasonic vocalizations during a light presentation. 
Overall, examining the individual effects of nicotine and phencyclidine, the interactions 
between these compounds and how a visual stimulus may affect ultrasonic vocalizations 
after drug treatment could preclinically delineate factors involved in the schizophrenia and 
nicotine addiction comorbidity.
Methods
Subjects
Forty-six adult male Sprague Dawley rats (275–299g upon arrival, Harlan, Indianapolis, IN, 
USA) were used in the final analysis. Two animals were excluded due to extremely high 
levels of 22 kHz vocalizations during an early session (e.g. over 500 vocalizations in 5 min), 
suggesting an acute stressor or pain that was not present in other animals. They were 
individually housed in clear rectangular polycarbonate tubs (48.3 cm × 26.7 cm × 20.3 cm) 
under 12-h light/dark conditions to avoid potential isolation-induced vocalizations. 
Experiments were conducted during the light cycle (light on between 06:00 and 18:00h). 
Room temperature was maintained at 22±1°C with a relative humidity of 45–60%. Water 
was continuously available and food was freely available. Animals were allowed 5 days of 
habituation to the animal facility before being used in experiments during which they were 
handled for 5 min per rat by each experimenter. All procedures were approved by the 
Institutional Animal Care and Use Committee at the University of Nebraska-Lincoln.
Apparatus
Eight identical two-way shuttle boxes custom designed and manufactured by Med 
Associates (St. Albans, VT) were used. Each box was housed in a ventilated, sound-
insulated isolation cubicle (96.52 cm W×35.56 cm D ×63.5 cm H). Each box was 64 cm 
long, 30 cm high (from grid floor) and 24 cm wide, and divided into two equal-sized 
compartments by a white PVC partition with an arch style doorway (15cm high × 9cm wide 
at base). An aluminum hurdle (4cm high) was placed between the two compartments. The 
grid floor consisted of 40 stainless steel rods with a diameter of 0.48 cm, spaced 1.6 cm 
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apart center to center. Two cue lights (28 volts) were mounted at the top of each 
compartment and a houselight (50 volts) was located at the top of each soundproof chamber. 
All testing procedures were controlled by Med Associates programs running on a computer. 
Background noise (approximately 74dB) was provided by a ventilation fan affixed at the top 
corner of each isolation cubicle.
In each two-compartment chamber, an ultrasonic vocalization microphone (P48 Avisoft 
Bioacoustics / Emkay Microphone, Avisoft Bioacoustics, Berlin, Germany) was mounted on 
the ceiling of the. The microphone was connected to a computer via an E-MU 0404 USB 
Audio device. Acoustic data were displayed in real time by the Avisoft RECORDER, a 
multi-channel triggering hard-disk recording software (version 3.4; Avisoft Bioacoustics), 
and were recorded at a sampling rate of 192 kHz in 16 bit format (version 4.51; Avisoft 
Bioacoustics). Recording of vocalization was started exactly 5 s prior to the Med Associates 
program and was manually synchronized before analysis.
Spectrograms were generated from the sound files using RavenPro 1.5 (Cornell Laboratory 
of Ornithology, Ithaca New York: 512 sample Fourier transformation with a Hann window 
function; filter bandwidth 135 Hz; frequency resolution 93.8 Hz; grid time resolution 2.13 
ms). Two trained scorers hand-counted both the 50 kHz and 22 kHz vocalizations with the 
criteria that 22 kHz vocalizations occurred in the range between 20 and 25 kHz and 50 kHz 
occurred between 30 and 95 kHz. Scorers classified the 50 kHz vocalizations into 14 
different categories (complex, composite, downward ramp, upward ramp, flat-trill 
combination, flat, short, inverted u, multistep, trill, trill with jumps, step down, step up, and 
split) based on the parameters set forth in Wright and colleagues (2010). The inter-rater 
reliability was assessed using a subset of 700 vocalizations, with 94% of calls receiving the 
same classification between scorers.
Procedure
Each rat was habituated to the chambers for 30 min per day for 2 days. During these 
habituation sessions, rats were placed into the chambers with a house light on. Rats were 
pre-injected with nicotine in their home cage 2 h after each habituation session, in order to 
potentially attenuate an initial aversion to nicotine (Bevins et al., 2001). After habituation, 
rats were randomly assigned to 6 groups based on the drugs administered before each drug 
testing session: SAL-SAL, SAL-NIC 0.2 mg/kg, SAL-NIC 0.4 mg/kg, PCP-SAL, PCP-NIC 
0.2 mg/kg, and PCP-NIC 0.4 mg/kg.
For a total of 7 daily drug testing sessions, rats were injected with drug (SAL, 2.0 mg/kg 
PCP and the corresponding NIC dose) and then placed into the chambers for 30 min. 
Ultrasonic vocalization was recorded during the entire 30-min session. During this time, 
lights were presented on a variable time (VT) 95 s schedule with an average of 19 
presentations per session. Light presentations involved the brief onset of the cue lights (5 s) 
and termination of the house light for 5 s. The exact time that the cue light was presented 
was recorded. Vocalizations were recorded over all 7 days of testing.
After the drug testing, rats underwent 7 days of no PCP or nicotine exposure. Rats were then 
placed into the vocalization recording chambers for a series of challenge days. During these 
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challenge days, all rats, regardless of their past drug treatment history, were tested under the 
same drug condition. On the 1st challenge day they received NIC (0.2 mg/kg). This was 
followed by NIC (0.4 mg/kg) and PCP (2.0 mg/kg) challenge days. The challenge days were 
presented in this order so as to keep constant the number of days of PCP non-exposure 
across animals.
Drugs
(−)Nicotine tartrate salt (Sigma, St. Louis, MO) was dissolved in 0.9% saline and adjusted to 
a pH of 7.0 ± 0.2 with a dilute NaOH solution. The high dose (0.4 mg/kg) was chosen based 
on previous research showing reinforcement-enhancement at that dose (Palmatier et al., 
2007, 2009) and, due to the potential of a ceiling effect, a further lower dose (0.2 mg/kg) 
was chosen on the basis of pilot data. Phencyclidine hydrochloride (PCP, a gift from NIDA 
Chemical Synthesis and Drug Supply Program) was obtained by mixing drug with 0.9% 
saline. Saline and PCP (2.0 mg/kg) were administered s.c. 10 min prior to placement in the 
chamber and nicotine (0.2 or 0.4 mg/kg) was administered s.c. 5 min prior to chamber 
placement. All doses are expressed as base. The dose of PCP was chosen on the bais of 
unpublished pilot data suggesting that this dose, combined with the nicotine doses, would 
affect ultrasonic vocalizations). This dose has also been used to model symptoms of 
schizophrenia in a similar regimen (Abdul-Monim et al. 2003, 2007; Jentsch et al. 1997).
Statistical Analyses
In order to determine if the vocalizations differed between the six groups and seven testing 
sessions, multiple ANOVAs were run. Factorial two-way ANOVAs targeted at the 
hypotheses were run to examine 50 kHz and 22 kHz vocalizations. In addition, two one-way 
ANOVAs were used to determine differences in the 50 kHz category types independently for 
the testing sessions, with group as the independent variable and the number of vocalizations 
in each category as the dependent variable. One-way ANOVAs were run to examine the 
differences on the challenge days with group as the independent variable and the number of 
50 kHz vocalizations as the dependent variable. Fisher’s least significant difference tests 
(LSD) were used as post hoc tests to attempt to protect from false positives with the 
minimum mean difference (mmd) reported. The significance level was set at 5% and was 
two-tailed.
Results
Total 50 kHz
Using targeted one-way ANOVAs to examine the hypotheses, we first looked at how PCP 
would affect vocalizations over days (see Figure 1). On Day 1, we found a marginally 
significant difference between PCP-SAL and SAL-SAL groups [F(1,14)=4.509, p=0.053]. 
PCP did not change 50 kHz vocalizations on days 2 through 7 (ps≥0.1). Fisher’s LSD tests 
showed that the PCP-SAL group had lower vocalizations on the first day compared to saline 
(p<0.02).
A one-way ANOVA comparing nicotine groups to saline was run to determine the effects of 
nicotine on 50 kHz vocalizations (see Figure 2). There was a significant difference between 
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groups on Day 7 [F(2,23)=4.99, p<0.05) but no significant differences on days 1 through 6 
(ps≥0.2). Fisher’s LSD tests showed that the low dose nicotine group was significantly 
different from saline (p<0.01). These results suggest that, after repeated exposure, low dose 
nicotine led to increased vocalizations in comparison to saline.
Finally, ANOVAs were run to compare the interaction between PCP and nicotine. There 
were no significant differences between the SAL-NIC 0.2 and PCP-NIC 0.2 groups on any 
days (ps≥0.3). There were also no significant differences between the SAL-NIC 0.4 and 
PCP-NIC 0.4 groups (ps≥0.2). These results suggest that the combination of nicotine and 
PCP did not affect vocalization rates after acute and repeated treatment.
50 kHz during Light
Examining 50 kHz USVs during light presentations, we found similar results (see Figure 3). 
There was a significant difference on Day 1 [F(1,14)=5.02, p<0.05] and a marginally 
significant difference on Day 2 [F(1, 14)=4.23, p=0.06]. There were no significant 
differences on days 3 through 7 (ps≥0.4). Fisher’s LSD tests showed that the PCP-SAL 
groups had lower 50 kHz USVs on Days 1 and 2 (ps≤0.02). These results suggest that PCP 
decreased 50 kHz vocalizations during light on the first day and marginally decreased 
vocalizations on Day 2.
In comparing 50 kHz USVs emitted during the light presentations for nicotine, we again 
found that there was a significant main effect of group [see Figure 4, F(2,23)=5.35, p<0.05]. 
LSD tests showed that there was a significant difference between both the low dose group 
(p<0.05) and the high dose group (p<0.05) compared to saline. There were no significant 
differences between groups on Days 1 through 6 (ps≥0.2). These results show that both low 
and high dose nicotine groups had higher levels of 50 kHz USVs during lights on the final 
day of testing.
Finally, interactions between nicotine and PCP were tested. No significant differences on 
any days were found when comparing SAL-NIC 0.2 to PCP-NIC 0.2 (ps≥0.09) or SAL-NIC 
0.4 to PCP-NIC0.4 (ps≥0.2). These results suggest that the combination of nicotine and PCP 
did not affect vocalization rates after acute and repeated treatment during the light stimulus.
50 kHz Categories
In addition to total vocalizations, the 50kHz USVs were separated into 13 different 
categories. Separate one-way ANOVAs were run to look at differences in the types of 50kHz 
calls emitted on the seven days of treatment (see Figure 5). On the first day, the groups 
showed significant differences in composite vocalizations [F(5,39)=2.87, p<0.05], as well as 
multistep vocalizations [F(5,39)=3.75, p<0.01]. Pairwise comparisons (LSDmmd=19.98) 
showed that the SAL-SAL group had more composite vocalizations than all other groups 
(ps≥0.014) and more multistep calls than all other groups (LSDmmd=18.62; ps≥0.014). In 
addition, there was a trend for a difference in upward ramp vocalizations between the groups 
[F(5,39)=2.45, p=0.05]. Pairwise comparisons (LSDmmd=43.72) revealed that the SAL-
SAL group produced more upward ramp vocalizations than the SAL-NIC 0.4, PCP-NIC 0.2 
and the PCP-NIC 0.4 groups (see Figure 5, ps≥0.019).
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There were no significant differences in the types of calls given by the groups on days 2 
through 6 (p≥0.08). On day seven there was a significant difference in the multistep calls 
between the six groups [F(5,39)=2.67, p<0.05]. Pairwise comparisons (LSDmmd=7.73) 
showed that the PCP-NIC 0.4 group had significantly fewer multistep vocalizations than the 
SAL-SAL and SAL-NIC 0.4 groups (p≤0.05). In addition, on day three, there was a 
significant difference in the number of uncategorized calls between the six groups 
[F(5,39)=2.71, p<0.05]. Pairwise comparisons (LSDmmd= 6.17) showed that the SAL-NIC 
0.4 group had significantly more uncategorized calls than all of the other treatment groups 
(p≤0.05). These calls looked similar to 50 kHz vocalizations but appeared in the 22 kHz 
range (see Figure 6).
22 kHz Vocalizations
There were no significant effects on any of the measures on total 22 kHz USVs (ps≥0.3) or 
22 kHz USVs during light stimuli (ps≥0.2). Only 19 total 22 kHz USVs were made on all 
drug testing days and only 1 vocalization was emitted during the light stimuli over days.
Challenge Days
The three challenge days showed significant differences in number of 50 kHz calls. On 
challenge day one, when rats were administered a low dose of nicotine (0.2 mg/kg), there 
was a significant difference in number of calls between the six groups, [see Figure 7, 
F(5,33)= 6.01, p< 0.001]. Pairwise comparisons (LSDmmd=352.19) indicated that the SAL-
NIC 0.4 group emitted significantly more vocalizations than all other groups (p≤0.005) 
except the SAL-NIC 0.2 group (p=0.051). In addition, the SAL-NIC 0.2 group produced 
significantly more vocalizations than the SAL-SAL group (p=0.01).
On challenge day two, when rats were administered a high dose of nicotine (0.4 mg/kg), 
there was a significant difference in the number of calls between the six groups [see Figure 
4, F(5,33)=3.25, p<0.05]. Pairwise comparisons (LSDmmd=229.16) indicated that the SAL-
NIC 0.4 group made significantly more vocalizations than all other groups (p<0.05).
On challenge day three, when rats were administered PCP, there was a significant difference 
in the number of calls between the six groups [see Figure 5, F(5,33)=8.35, p<0.02]. Pairwise 
comparisons (LSDmmd=503.99) showed that the PCP-NIC 0.2 and PCP-NIC 0.4 groups 
were not significantly different (p=0.06), and these two groups produced significantly more 
vocalizations than the other groups (p<0.001).
Discussion
First, we found that nicotine and PCP altered total vocalizations in an opposing fashion: 
PCP, after acute treatment, seemingly decreased total 50 kHz vocalizations while nicotine 
treatment led to higher total vocalizations compared to control groups but only after repeated 
exposures. Similar findings were seen in the 50 kHz vocalizations during the visual stimulus 
presentations. There were no differences in 22 kHz vocalizations. When considering 
categories of vocalizations, specific subtypes were differentially affected by nicotine and 
PCP treatment. Finally, no consistent interactions were seen during acute and chronic PCP 
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treatment but only animals that had received both nicotine and PCP had higher vocalizations 
in compared to all other groups on challenge sessions.
Examining overall vocalizations elicited throughout the session, acute PCP exposure 
appeared to produce a more negative affective state, as shown by a decrease in 50 kHz 
vocalizations. This finding is analogous to the recent study showing that PCP attenuated 
tickling-induced 50 kHz vocalizations (Boulay et al., 2013). While this experiment had a 
number of methodological differences (i.e. different age of rat, tickling-induced 
vocalizations, different dosage), the similarities between the findings suggest that the 
attenuation of 50 kHz USVs by PCP is a relatively robust effect. Boulay and colleagues 
(2013) suggested that this decrease may model anhedonia (a negative symptom of 
schizophrenia) and the results of the present study support this idea. Contrary to research on 
“aversive” vocalizations (Tunstall et al., 2009), PCP did not increase 22 kHz vocalizations in 
this paradigm, but only altered 50 kHz USVs, suggesting that decreases in the 50 kHz 
vocalizations might be a better measure to examine reinforcement differences.
Contrary to the effects of PCP on 50 kHz vocalizations, the group receiving the high dose of 
nicotine had higher levels of vocalizations associated with positive affective states in 
comparison to control groups, but this effect was only seen after repeated nicotine exposure. 
In previous studies, acute nicotine did not produce significant changes in total numbers of 50 
kHz USVs (Simola et al., 2012) but repeated nicotine treatment led to increased 
vocalizations over days (Simola et al. 2013). Our findings support these previous findings in 
terms of acute and chronic effects, with nicotine producing no significant effect on the first 
day but causing increased numbers of USVs in comparison to saline on the final day of 
treatment. Similarities between these results suggest that repeated exposure may be 
necessary to see the reinforcing activity of nicotine in the ultrasonic vocalization paradigm. 
Repeated nicotine exposure is integral in other paradigms and appears to be integral to 
development of reinforcement-enhancement effects of nicotine (Barrett & Odum, 2011; 
Palmatier et al., 2007; Raiff & Dallery, 2006) As alterations in rates of ultrasonic 
vocalizations may potentially be used to elucidate mechanisms behind drug dependence, 
such as sensitization and tolerance (Taracha et al., 2007), exploring the mechanisms behind 
this repeated effect of nicotine and its relationship to behavioral and neurobiological factors 
involved in drug dependence is vital to further detail the importance and validity of 
examining ultrasonic vocalizations for drug addiction measures.
Vocalizations during light presentations were examined, in addition to overall vocalizations, 
to determine if USVs might be sensitive enough to illuminate differences in the 
reinforcement-enhancement effects of drugs. Reinforcement-enhancement was hypothesized 
to be seen as an increase in ultrasonic vocalizations during a light presentation. However, 
overall vocalizations did not seem to change significantly during light presentations (not 
shown) and temporal patterns were fundamentally similar to those seen during no light 
presentation, although the effects of PCP lasted longer when examining vocalizations during 
light. It is possible that this paradigm is not sensitive enough to fully detail the 
reinforcement-enhancement effect of drugs. It is also possible that the reinforcing value of 
the stimuli might not be sufficient to detect differences. The non-contingent nature of the 
stimuli could potentially reduce the reinforcing value of the visual stimulus or the length of 
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the visual stimulus may have been too short, as others have used significantly longer stimuli 
(Barrett & Bevins, 2012; Caggiula et al., 2002; Chaudhri et al., 2007; Donny et al., 2003; 
Palmatier et al., 2006). Future research to determine if the reinforcement-enhancement 
effects of nicotine can be seen in this paradigm is warranted, as ultrasonic vocalizations do 
not rely on locomotor activity, which can significantly affect operant behavior typically used 
to study reinforcement-enhancement.
We also found that different subtypes of 50 kHz vocalizations were differentially affected by 
acute treatment of both PCP and nicotine. Both PCP and nicotine significantly decreased 
composite and multistep subtypes of vocalizations after acute treatment. Rats that had 
previously received nicotine had fewer upward ramp vocalizations yet the numbers of total 
vocalizations were not significantly different. All of the subtypes affected by both nicotine 
and phencyclidine exposure were frequency-modulated; there were no differences in either 
total or light-paired flat vocalizations. In addition, nicotine did not alter trill vocalizations, in 
agreement with the findings of Simola and colleagues (2014). The importance of subtypes is 
not currently known but different categories of vocalizations have been hypothesized to have 
different behavioral significance (Wright et al., 2010). Since 50 kHz calls can occur in 
potentially aversive situations (see Wohr et al., 2008 for discussion), examination of specific 
subcategories of 50 kHz vocalizations might be better suited to examining reward and 
reinforcement. For example, frequency modulated calls such as trills are associated with 
appetitive stimuli (Ahrens et al., 2009; Burgdorf et al., 2007; Burgdorf & Panksepp, 2006; 
Wohr et al., 2008), while flat vocalizations are observed in non-appetitive situations such as 
during short periods of isolation (Stevenson et al., 2009; Wohr et al., 2008).
Vocalization analysis not only uncovered differences in established 50 kHz subtypes but 
additional vocalizations resembling 50 kHz subtypes were seen in the range associated with 
22 kHz vocalizations (see Figure 7). These vocalizations were placed into the uncategorized 
vocalization subtype and a potentiation of total vocalizations in this category was seen in the 
SAL-NIC 0.4 group. Given that differences in 50 kHz USVs may have different behavioral 
implications, it is possible that subtypes of 22 kHz vocalizations might also be associated 
with different features. 22 kHz calls have been examined for the temporal nature 
(Brudzynski et al. 1993) and frequency of modulation (see Litvin et al., 2006, Vivian & 
Miczek, 1993a, b) and considerably short 22 kHz vocalizations have been found during drug 
treatment (Barker et al. 2010). To the authors’ knowledge, USVs in the 22 kHz range 
resembling the vocalizations found in this experiment have not previously been identified. 
Further replication of this USV subtype and experimentation involving devocalization 
surgery is necessary but these results are intriguing, especially given the differences seen in 
these vocalizations after nicotine treatment.
The previous discussion has focused on the acute and chronic exposure to PCP and nicotine. 
In these two treatment regimens, no interaction was found between nicotine and 
phencyclidine. Interactions were, however, seen on challenge days. On the nicotine 
challenge days, only a basic sensitization effect was seen; previous exposure to nicotine 
(either with or without PCP on board) led to increased 50 kHz vocalizations. However, the 
most interesting findings occurred on the PCP challenge day. Rats that had received both 
nicotine and PCP had higher levels of vocalizations on the PCP challenge day; this was 
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significantly different from rats that had only received PCP and groups that had only 
received nicotine.
The finding that an interaction between PCP and nicotine is only seen on challenge days is 
consistent with findings on the differential effects of PCP treatment regimens on 
schizophrenia-related behaviors. Acute exposure, chronic exposure and cessation from PCP 
treatment consistently show behavioral differences in a number of paradigms, specifically in 
relation to negative symptoms (for review, see Neill et al., 2013). Here we see that the 
interaction between the two drugs is only seen after PCP treatment has been discontinued. It 
is possible that rodents in this animal model of negative symptoms of schizophrenia might 
be more sensitive to reinforcing effects of nicotine after cessation of PCP treatment, given 
the increase in 50 kHz USVs seen only in the groups with the pairing. Thus, this 
discontinuation model may be better suited to modeling negative symptoms of schizophrenia 
(Ellenbroek & Cools, 2000). It may be possible, therefore, that schizophrenia patients with a 
higher preponderance of negative symptoms may be more sensitive to the reinforcing effects 
of nicotine, which could increase nicotine use. While some human research supports this 
suggestion, such as work by Ahnallen & colleagues (2012) showing that the severity of 
anhedonia is correlated with the severity of nicotine dependence, it is still speculative and 
there is a clear need for more research on this idea. Another possibility is that effects on the 
PCP challenge day may be influenced by the conditioning between PCP and nicotine. The 
interoceptive state of PCP could act as a cue to “predict” nicotine, with the lack of nicotine 
or the previous conditioning of the PCP/nicotine combination influencing USVs. Further 
research on the effects of conditioning is needed to elucidate the mechanisms behind the 
challenge day difference.
Overall, this experiment suggests that both PCP and nicotine alter 50 kHz vocalizations, in 
different ways. PCP acutely decreased 50 kHz vocalizations while repeated exposure to 
nicotine led to higher levels of 50 kHz vocalizations. Specific frequency-modulated 
vocalizations were lessened by nicotine and PCP. This is the first study to report differences 
in subtypes of vocalizations due to PCP exposure. Given the complexities of the PCP model 
of schizophrenia symptoms, examination of different call profiles of animals in this model is 
warranted and further examination of the interaction of antipsychotics with this effect would 
be illuminating. Vocalization subtypes resembling those seen in the 50 kHz categories were 
also noted in the 22 kHz range. Given that these vocalizations were increased after nicotine 
treatment, future research on the potential mechanisms and behavioral significance of these 
vocalizations is necessary. Finally, this study lends credence to the idea that examining 
behaviors after discontinuation of PCP may better model discrepancies in reward and 
reinforcement seen in patients with schizophrenia that might not be uncovered during acute 
and chronic treatment.
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Figure 1. 
PCP and SAL group 50 kHz vocalizations (mean+ SEM) by day. The PCP-SAL group 
emitted fewer 50 kHz vocalizations in comparison to the SAL-SAL group on the first day 
according to LSD tests * p<0.05, n=7 and n=8 respectively
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Figure 2. 
Effect of nicotine (mean + SEM) on 50 kHz vocalizations over all days of drug testing. The 
low dose nicotine group emitted more 50 kHz vocalizations than the SAL-SAL group. * 
p<0.05. SAL-SAL, n=7/group; nicotine, n=8/group.
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Figure 3. 
Effect of PCP (mean ± SEM) on 50 kHz vocalizations emitted during light stimuli, over 
days of drug testing. The PCP-SAL group made fewer vocalizations than the SAL-SAL 
group on the first and second day according to LSD tests. * p<0.05.
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Figure 4. 
Effect of nicotine (mean + SEM) on 50 kHz vocalizations emitted during light stimuli over 
drug testing days. The low dose nicotine group and high dose nicotine group emitted more 
50 kHz vocalizations than the SAL-SAL group. * p<0.05.
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Figure 5. 
Differences between groups on the first drug session in subtypes of 50 kHz vocalizations 
(mean + SEM). SAL-SAL had higher composite and multistep vocalizations than all other 
groups and groups that had previously received high dose nicotine (0.4 mg/kg) had lower 
upward ramp vocalizations. #p=0.50; * p<0.05. n= 7 or 8/ group.
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Figure 6. 
Examples of vocalizations that look like subtypes of 50 kHz vocalizations but were within 
the range of 22 kHz vocalizations.
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Figure 7. 
Overall 50 kHz vocalizations (mean + SEM) on the low -dose nicotine challenge day, 
separated by group. Rats that had previously received any dose of nicotine had higher 
vocalizations than the SAL-SAL group. * p<0.05
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Figure 8. 
Overall 50 kHz vocalizations (mean + SEM) on the high-dose nicotine challenge day, 
separated by group. Only rats that had previously received SAL-NIC 0.4 had higher 
vocalizations than the SAL-SAL group. * p<0.05
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Figure 9. 
Overall 50 kHz vocalizations (mean + SEM) on the PCP challenge day, separated by group. 
Groups that had previously received both nicotine and PCP (either dose) had higher 
vocalizations than the SAL-SAL and PCP-SAL groups. * p<0.05
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